Onera Health announces the launch of Onera Polysomnography-as-a-Service in selected European markets at the International Congress 2022 of the European Respiratory Society (ERS). EINDHOVEN, The Netherlands–(BUSINESS WIRE)–Onera Health, a leader in transforming sleep medicine and remote monitoring, announced today the official launch of its ground-breaking solution to diagnose sleep disorders in Europe. The service is … [Read more…]
Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD, AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with … [Read more…]
EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC., the makers of synthetic control cells for cell analysis applications, including flow cytometry, enabling precise, reliable, and repeatable results, today announced they had extended their distribution channel through a new agreement with BIOKÉ, an experienced and knowledgeable company from the Netherlands that provides innovative products with the highest quality in … [Read more…]
Oral presentation in “Investigational Immunotherapy” session on Saturday, September 10 at 2:45 PM CEST MUNICH–(BUSINESS WIRE)–CatalYm today announced that the mature results from its Phase 1, first-in-human trial “GDFATHER-1” (GDF-15 antibody-mediated human effector cell relocation) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022. The trial evaluated … [Read more…]
ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product, at the European Society for Medical Oncology … [Read more…]
Zanidatamab zovodotin shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers Results to be reviewed in an oral presentation at European Society for Medical Oncology (ESMO) Congress 2022 in Paris Monday, September 12 at 5:25 pm Central European Summer Time (CEST) VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. … [Read more…]
— Progression-Free Survival Efficacy of Trodelvy Consistent with That Observed in the TROPiCS-02 Intention-to-Treat Population — — Results Presented at ESMO 2022 Highlight Trodelvy as a Potential Treatment Option in HR+/HER2-Low and IHC0 Status Metastatic Breast Cancer — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post hoc subgroup … [Read more…]
In Phase 1 studies, cudetaxestat displayed low potential for drug-drug interactions when dosed with approved therapies for idiopathic pulmonary fibrosis (IPF) and other commonly used medications Cudetaxestat was well tolerated and showed no reports of treatment-related serious adverse events, including when co-administered with either pirfenidone or nintedanib, in healthy volunteers Cudetaxestat, an investigational non-competitive autotaxin … [Read more…]
Honoring blood collection professionals and their lifesaving impact on patient care LAKE ZURICH, Ill. & BETHESDA, Md.–(BUSINESS WIRE)–#BloodCollectorsWeek–Fresenius Kabi and AABB announced today the official start of the 17th annual Blood Collectors Week celebration, which runs September 4-10, 2022. Throughout the week, blood collectors are being honored for the lifesaving work they do each day … [Read more…]
The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the AeriSeal System REDWOOD CITY, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–$LUNG #COPD–Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the … [Read more…]
